Figure 3

773 × 547px · 168.5 केबी

Source Paper

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Pharmaceuticals (Basel, Switzerland) (2025)

PMID: 40006091

DOI: 10.3390/ph18020279

Cite This Figure

![Figure 3: Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.](https://pdfs.citedhealth.com/figures/40006091/231.png)

> Source: Daniela Ciobârcă et al. "Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (." *Pharmaceuticals (Basel, Switzerland)*, 2025. PMID: [40006091](https://pubmed.ncbi.nlm.nih.gov/40006091/)

<figure>
  <img src="https://pdfs.citedhealth.com/figures/40006091/231.png" alt="Figure 2. NBCs with potential therapeutic roles in T2D and MASLD." />
  <figcaption>Figure 3. Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.<br>  Source: Daniela Ciobârcă et al. "Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2025. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40006091/">40006091</a></figcaption>
</figure>

More Figures from This Paper

Figure 3

Source Paper

Cite This Figure

संबंधित साक्ष्य